The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Cellular and Molecular Biology is a prominent academic journal published by C M B ASSOC, specializing in the dynamic fields of cellular and molecular biology. Established in 1977, this journal has consistently aimed to disseminate groundbreaking research that contributes to our understanding of biochemical processes, cell dynamics, and molecular mechanisms governing life. With its ISSN 0145-5680 and E-ISSN 1165-158X, the journal plays a vital role in the exchange of innovative ideas, evidenced by its coverage of research from 1977 to 2024. Although currently categorized in the Q4 quartile for major disciplines such as Biochemistry and Cell Biology, it is dedicated to fostering the development of the field by welcoming submissions that challenge the conventional understanding and lead to novel insights. Researchers and academics looking to contribute to or stay updated in the rapidly evolving landscape of molecular biology will find this journal a valuable resource for connecting with a global community of scientists.

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

BIOLOGICAL PROCEDURES ONLINE is a premier open-access journal published by BMC, dedicated to advancing the fields of biochemistry, genetics, and molecular biology. With its electronic ISSN 1480-9222 and a strong commitment to accessibility since 2009, this journal provides a vital platform for researchers and scholars to disseminate their findings and foster collaboration within the scientific community. Based in the United Kingdom, this journal has garnered an impressive reputation, achieving Q1 status in the 2023 category rankings, with notable inclusion in the Scopus rankings, placing it in the 86th percentile among 221 peer journals in the general biochemistry, genetics, and molecular biology domain. It covers a broad range of topics, ensuring coverage of the latest advancements and methodologies in biological procedures, making it an essential resource for academics, practitioners, and students alike. Researchers are encouraged to submit their innovative work and contribute to the ongoing dialogue in this dynamic and ever-evolving field.

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

Wspolczesna Onkologia - Contemporary Oncology is a leading open-access journal dedicated to the field of oncology and radiology, published by TERMEDIA PUBLISHING HOUSE LTD since 1999. With its ISSN 1428-2526 and E-ISSN 1897-4309, the journal has established a prominent place in scholarly publishing, contributing significantly to the advancement of cancer research and treatment modalities. Located in Poznań, Poland, it operates within a framework of high academic standards, currently holding a Q3 quartile ranking in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging for the year 2023. The journal serves as a valuable resource for researchers, medical professionals, and students alike, providing a platform for innovative studies and reviews that drive the clinical application of oncological practices. With its commitment to open access, Wspolczesna Onkologia allows for widespread dissemination of knowledge, ensuring that cutting-edge research is accessible to a global audience, thus bridging gaps in cancer care and fostering collaborative advancements in the field.

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.